Scorpius Holdings, Inc. reported significant financial challenges in its latest 10-Q filing for the quarter ending June 30, 2025. The company generated revenue of $227,534 for the three months ended June 30, 2025, a substantial decline from $759,944 in the same period of the previous year. For the six months ending June 30, 2025, total revenue was $439,798, down from $4.27 million in the prior year. The operating loss for the quarter was $5.78 million, compared to a loss of $9.26 million in the same quarter of 2024. The net loss attributable to Scorpius Holdings was $4.08 million for the quarter, translating to a loss per share of $0.09, a notable improvement from a loss of $26.98 per share in the prior year.
The company’s financial position has deteriorated significantly, with total assets dropping to $21.57 million as of June 30, 2025, down from $39.18 million at the end of 2024. Current liabilities also increased slightly to $23.28 million, while total liabilities reached $29.49 million. The accumulated deficit has grown to $301.97 million, raising concerns about the company's ability to continue as a going concern. Scorpius has indicated that it may need to file for bankruptcy or liquidate if it cannot secure additional funding or find a strategic partner.
Operationally, Scorpius has faced setbacks, including the termination of its lease for its manufacturing facility in San Antonio due to non-payment of rent. The company has ceased operations and does not anticipate generating revenue unless it can engage in a strategic transaction, such as a merger or acquisition. The filing also noted that the company has no assets capable of generating revenue following the sale of its biomanufacturing facility assets for $16.25 million in December 2025.
In terms of strategic developments, Scorpius has been exploring various financing options, including equity and debt financing, to address its liquidity needs. The company raised $1.94 million through a private placement of common stock during the quarter. However, as of the filing date, Scorpius had only $520,518 in cash and cash equivalents, which is insufficient to cover its operational expenses beyond January 2026. The company has acknowledged substantial doubt about its ability to continue as a going concern and is actively seeking strategic alternatives to stabilize its financial situation.
About Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is a contract development and manufacturing organization (CDMO) specializing in biologics, cell- and gene-based therapies, and large molecule biologics. It offers process development, CGMP manufacturing, and quality control services primarily to biotech and pharma clients. The company operates a modern facility in Texas, supports U.S. government contracts, and emphasizes American-made equipment and domestic sourcing to enhance competitiveness.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.